MSCLF News and Press, Satellos Bioscience Inc.

BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” o...

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ Satellos Bioscience Inc . (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing lif...

Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc . (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology...

Satellos Bioscience Inc . (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announces that the Company has completed a consolida...

- Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne - Study endpoints include safety and tolerability, effect on muscle force and function, and impact on muscle quality and regeneration - Enrollment of first s...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the following investor confer...

Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify AAK1 as a paradigm shifting drug target to restore muscle repair and regeneration in Duchenne muscular dystrophy Publication av...

2025-11-14 13:47:48 ET More on Satellos Bioscience Inc. Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy Seeking Alpha’s Quant Rating on Satellos Bioscience Inc. Historical earnings data for Satellos Bioscience Inc. Financ...

Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission to the U.S. FDA and global regulatory filings to advance a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dy...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...